The anticipated size of the herpes simplex keratitis treatment market in 2022 was US$ 4,237.2 million and is estimated to be US$ 4,442.2 million in 2023. There are a few key factors that are anticipated to expand the herpes simplex virus treatment market such as:
According to the Future Market Insights analysis report, herpes simplex keratitis treatment market is projected to expand at a CAGR of 6.1% between 2023 and 2033, totaling around US$ 8,022.9 million by 2033.
The ongoing development of advanced healthcare infrastructures worldwide is likely to augment the demand for herpes simplex keratitis treatment in the assessment period. Herpes simplex virus keratitis is an infection of epithelial cells that are present on the surface of the eye. It also causes retrograde infection of nerves that serve the cornea.
Primary infection usually leads to the swelling of eyelids and the conjunctiva, as well as itchy, white lesions on the corneal surface. Some of the additional symptoms include sinusitis, mild to acute dryness, and dull pain in the eye.
Recurrent infection is often caused by the reactivation of the virus and transportation of the same from the nerve axon to sensory nerve endings. Antiviral treatment either in the form of topical medications or oral administration of famciclovir or valacyclovir for 10 to 14 days is required when keratitis occurs. The condition is diagnosed by a slit-lamp examination. The rising adoption of topical therapy owing to its high efficacy is anticipated to propel the market in the future years.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2022) | US$ 4,237.2 million |
| Projected Forecast Value (2023) | US$ 4,442.2 million |
| Projected Forecast Value (2033) | US$ 8,022.9 million |
| Growth rate | 6.1% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Global herpes simplex keratitis treatment market expanded at a CAGR of 3.9% between 2018 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 6.1% between 2023 and 2033.
Therapeutics segment includes valacyclovir drug considerably dominates the market as it is cost-effective, easily available, and effective in blocking the virus from reproducing in the body, thereby having advantages to controlling the symptoms of an outbreak.
Valacyclovir is most widely used for cold sores determinable to its high absorption rate. Efforts and investments are done for providing vaccination for the disease condition which is anticipated to boost the growth of the vaccine segment.
Increasing Research and Development Activities
Increasing research and development activities conducted by numerous key players to launch new drugs are set to propel the market in the near future. The rising cases of herpes simplex virus type 2 and herpes simplex virus type 1 across the globe is another key factor that is estimated to bode well for the herpes simplex keratitis treatment market growth.
According to the World Health Organization (WHO), nearly 3.7 billion people under the age of 50 years have herpes simplex virus type 1 infection across the globe, whereas around 491 million people aged 15 to 49 years have herpes simplex virus type 2 infection. These numbers are set to surge in the upcoming years, thereby propelling the growth in this market.
Principal Consultant
Cost of Herpes Simplex Keratitis Treatment is High
The cost of herpes simplex keratitis treatment is high. As per a study conducted by a team of researchers at Saint Louis University, Missouri, people in the United States spend tens of millions for the treatment of this condition. Moreover, people, especially in emerging economies may not be able to spend a huge amount and this may hamper the herpes simplex keratitis treatment market growth in the future.
North America is projected to remain at the forefront by procuring the notable herpes simplex keratitis treatment market share of 34.7% in the near future. Further, the increasing prevalence of infections associated with the herpes simplex virus in the United States is a leading factor that is likely to propel the market with a value share of 32%.
Sexually active individuals or those who have had 3 or more sex partners in their lifetime are at a high risk of developing type 1 keratitis.
According to the Centers for Disease Control and Prevention (CDC), 1 in 5 individuals have a Sexually Transmitted Infection (STI), such as genital herpes in the United States, totaling around 68 million infections. In addition to that, new STIs total around US$ 16 billion in direct medical costs. This trend is projected to continue throughout the evaluation period, thereby boosting North America’s market.
The growing number of new product launches by reputed companies is expected to fuel the sales of herpes simplex keratitis treatment options in Asia Pacific. The surging number of clinical trials in China, India, and Australia is another significant factor that is estimated to augur well for the market. China is forecasted to expand at a CAGR of 7.8%, whereas India is forecasted to expand at 7.1% CAGR. Australia is forecasted to capture 8.4% CAGR. For example,
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Acyclovir has a significant position in the market with a value share of 29.8%. Acyclovir and its analogs, are considered to be the inhibitors of viral DNA replication and are the only approved medicines for HSV that are used for infection therapies.
Topical route of distribution holds a leading position in the market with a value share of 43.8%. Host tissue (cornea) may become effective for HSV infection and repetition with topical, intravitreal, or systemic medications. In humans, recurrent ocular HSV-1 disease has mainly contributed to the usage of prostaglandin agonists, corticosteroids, and inhibitors of angiogenesis.
The global herpes simplex keratitis treatment market contains a large number of big and small players. Some of them include Aurobindo Pharma, GlaxoSmithKline, Cipla, Blistex, Mylan, Vectans Pharma, Dr. Reddy's Laboratories, Bausch Health, Novartis International AG, and Jubilant Cadista among others.
The majority of the leading companies are increasingly focusing on mergers and acquisitions, as well as geographical expansions to gain a competitive edge in the market. Meanwhile, a few other key players are striving to come up with innovative products to fulfill the high unmet needs of patients across the globe.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 6.1% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug, Route of Administration, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia & Pacific; East Asia; The Middle East & Africa |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, Russia, Poland, Czech Republic, Romania, China, Japan, South Korea, India, Bangladesh, Australia, New Zealand, GCC countries, South Africa, Israel |
| Key Companies Profiled | GlaxoSmithKline; Vectans Pharma; Blistex; Bausch Health; Aurobindo Pharma; Dr. Reddy's Laboratories; Cipla; Jubilant Cadista; Mylan; Novartis International AG |
| Customization | Available Upon Request |
The market is estimated to secure a valuation of US$ 4,442.2 million in 2023.
The global market size is expected to reach US$ 8,022.9 million by 2033.
The growth potential of the market is 6.1% through 2033.
Persistent research and development efforts are helping the market advance.
High cost of herpes simplex keratitis treatment is derailing the market growth.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033
5.3.1. Famciclovir
5.3.2. Valacyclovir
5.3.3. Acyclovir
5.3.4. Other Drugs
5.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Topical
6.3.2. Injection
6.3.3. Oral
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Drug
8.2.3. By Route of Administration
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug
8.3.3. By Route of Administration
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug
9.2.3. By Route of Administration
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug
9.3.3. By Route of Administration
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Drug
10.2.3. By Route of Administration
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug
10.3.3. By Route of Administration
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Drug
11.2.3. By Route of Administration
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug
11.3.3. By Route of Administration
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Drug
12.2.3. By Route of Administration
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug
12.3.3. By Route of Administration
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug
13.2.3. By Route of Administration
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug
13.3.3. By Route of Administration
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Drug
14.2.3. By Route of Administration
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug
14.3.3. By Route of Administration
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Drug
15.1.2.2. By Route of Administration
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Drug
15.2.2.2. By Route of Administration
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Drug
15.3.2.2. By Route of Administration
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Drug
15.4.2.2. By Route of Administration
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Drug
15.5.2.2. By Route of Administration
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Drug
15.6.2.2. By Route of Administration
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Drug
15.7.2.2. By Route of Administration
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Drug
15.8.2.2. By Route of Administration
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Drug
15.9.2.2. By Route of Administration
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Drug
15.10.2.2. By Route of Administration
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Drug
15.11.2.2. By Route of Administration
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Drug
15.12.2.2. By Route of Administration
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Drug
15.13.2.2. By Route of Administration
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Drug
15.14.2.2. By Route of Administration
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Drug
15.15.2.2. By Route of Administration
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Drug
15.16.2.2. By Route of Administration
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Drug
15.17.2.2. By Route of Administration
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Drug
15.18.2.2. By Route of Administration
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Drug
15.19.2.2. By Route of Administration
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Drug
15.20.2.2. By Route of Administration
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Drug
15.21.2.2. By Route of Administration
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Drug
15.22.2.2. By Route of Administration
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Drug
15.23.2.2. By Route of Administration
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug
16.3.3. By Route of Administration
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. GlaxoSmithKline
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Vectans Pharma
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Blistex
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Bausch Health
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Aurobindo Pharma
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Dr. Reddy's Laboratories
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Cipla
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Jubilant Cadista
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Mylan
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Novartis International AG
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Pfizer Inc.
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Sanofi S.A.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. Merck & Co., Inc.
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Herpes Simplex Keratitis Treatment Market
